MELINTA THERAP
SpecialtyMELINTA THERAP is a specialty pharmaceutical company focused on Infectious Disease, Dermatology, Cardiovascular. Key products include ORBACTIV.
MELINTA THERAP at a Glance
- Strong track record with 84% execution quality across 29 trials
- Fast trial execution (11 months median completion)
Upcoming FDA Decisions
Full Calendar →MELINTA THERAP's Key Drugs
MELINTA THERAP's core commercial portfolio centers on ORBACTIV, KIMYRSA, spanning Infectious Disease and Dermatology — its most strategically important drugs approved in the last 15 years.
MELINTA THERAP's Recent FDA Approvals
New NDA/BLA approvals for MELINTA THERAP over the last two years — novel drugs only, excluding generics and label supplements.
MELINTA THERAP's Therapeutic Areas
MELINTA THERAP's approved drugs and pipeline span 4 therapeutic areas, led by Infectious Disease and Dermatology, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
MELINTA THERAP's Top Competitors
MELINTA THERAP's closest competitors by therapeutic-area and drug-target overlap include APOTHECON, Baxter, and B BRAUN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
MELINTA THERAP Pipeline Snapshot
MELINTA THERAP has 29 active clinical programs from ClinicalTrials.gov — 12 Phase 3, 10 Phase 2 and 7 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ORBACTIV leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 9/11 completed
- • Speed: 11 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges